Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average rating of “Moderate Buy” from ...

Amylyx is progressing promising treatments for Wolfram Syndrome and Progressive Supranuclear Palsy with potential phase 3 trials. Learn more on AMLX stock here.

CAMBRIDGE, Mass., November 27, 2024--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that management will ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the 7th Annual Evercore ISI ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the 7th Annual Evercore ISI HealthCONx Conference. The ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--$AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will ...

Amylyx Pharmaceuticals, Inc. (AMLX) (“Amylyx” or the “Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

This page features the latest news about the Amylyx Pharmaceuticals stock. Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA for the ...